COVID-19 Vaccination During Pregnancy Leads to Improved Neonatal Outcomes Without Increased Maternal Risks
Research shows COVID-19 vaccination during pregnancy reduces infection risk and improves neonatal outcomes without increasing maternal health risks, supporting its safety and efficacy.
Recent research has demonstrated that COVID-19 vaccination during pregnancy offers significant health benefits for both mothers and their newborns, without adding health risks to the mother. An extensive analysis of over 1.2 million pregnant individuals revealed that vaccinated women experienced a 58% reduction in the risk of COVID-19 infection. Additionally, vaccination was linked to a decrease in adverse pregnancy outcomes, including an 8% lower chance of preterm birth before 37 weeks and a 34% reduction in preterm births before 28 weeks.
The study, titled "Safety and Efficacy of Maternal COVID-19 Vaccination During Pregnancy: Umbrella Review & Meta-Analyses," compiled data from 23 meta-analyses encompassing more than 200 studies. Conducted by researcher and Harvard University fellow Nikan Zargarzadeh, the review suggests that vaccination during pregnancy also lowers the risk of stillbirth by 25%, reduces the likelihood of neonatal intensive care admissions by 9%, and decreases the incidence of congenital anomalies by 17%. Importantly, no increased risks were observed concerning maternal health, including hospitalization, intensive care needs, gestational diabetes, hypertension, or pre-eclampsia.
The findings, shared during the American Academy of Pediatrics 2025 National Conference & Exhibition, reinforce the safety and benefits of COVID-19 vaccination for pregnant individuals. These results can provide valuable guidance for healthcare providers and pregnant women making informed vaccination decisions.
Source: https://medicalxpress.com/news/2025-09-covid-vaccination-pregnancy-neonatal-outcomes.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Promising Oral Medication Improves Heart and Muscle Symptoms in Barth Syndrome
A new oral drug, MA-5, shows promising results in improving heart and muscle symptoms in Barth syndrome by targeting mitochondrial dysfunction. This breakthrough could lead to disease-modifying treatment options.
Reconstruction of the 1918 Influenza Virus Genome from Swiss Historical Specimen
A groundbreaking study recovered the complete genome of the 1918 influenza virus from a Swiss historical specimen, revealing key adaptations that helped the virus infect humans during the pandemic. This research enhances our understanding of viral evolution and pandemic preparedness.
Continued Investment in Biopharmaceutical Innovation After Inflation Reduction Act Approval
Recent studies show that biopharmaceutical companies continue to invest heavily in R&D and acquisitions despite the Inflation Reduction Act, challenging the notion that drug price controls will dampen innovation.
Gene Variant Providing Protection Against Heart Diseases Offers Hope for Safer Therapies
Genetic variations in the IL6 gene suggest that reducing IL-6 activity can lower cardiovascular risk without increasing infection susceptibility, supporting safer therapeutic strategies.